Lorvotuzumab Biosimilar Antibody-Drug Conjugate (CD56) for Research

Cat No.: GMP-Bios-ab-323

Pre-Made Lorvotuzumab biosimilar, Whole mAb ADC, Anti-NCAM1 Antibody: Anti-CD56/NCAM/MSK39 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC).

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-323-1mg 1mg
GMP-Bios-ab-323-10mg 10mg
GMP-Bios-ab-323-100mg 100mg
GMP-Bios-ab-323-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Lorvotuzumab biosimilar, Whole mAb ADC, Anti-NCAM1 Antibody: Anti-CD56/NCAM/MSK39 therapeutic antibody
INN Name Lorvotuzumab
TargetNCAM1
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesImmunoGen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMultiple myeloma;Solid tumours;Small cell lung cancer
Development Techna



About target - NCAM1

1. Protein Neural cell adhesion molecule 1

2. Gene NCAM1

3. Organism Homo sapiens (Human)

Function
This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.

(Microbial infection) Acts as a receptor for rabies virus.

(Microbial infection) Acts as a receptor for Zika virus.